Abstract
Epidemiological surveys demonstrate undoubtedly that cardiovascular disorders caused or associated with hypertension are at a high risk of non-fatal or fatal events and occurring with a great rate. Ischaemic heart disease with effort angina and myocardial infarction, often unrecognized myocardial infarction, stroke and transient ischaemic attack may be observed more frequently than other cardiovascular disorders in hypertensive patients.
Large-scale trials do not support the hypothesis that effective benefits are reached by current non-pharmacological or pharmacological prevention which need enormous costs to public health.
Lowering blood pressure is the main target to reach in an attempt to reduce cardiovascular complications in hypertensive patients. Therefore, the costs-benefit ratio, which estimates public health costs, needs yet marked improvement since the public health expenses are heaviest with results that do not support the economic effort.
Statistically, quantitative measures to modify the current regimen need to better evaluate both public health costs and reached benefits.
Keywords: Epidemiological transition, hypertension, cardiovascular disorders, trial(s), cost-benefit ratio, smoking, lipoproteins, vulnerable plaque, thrombin, diabetes
Current Pharmaceutical Design
Title: Epidemiology and Costs of Hypertension-related Disorders
Volume: 17 Issue: 28
Author(s): Aldo Leone, Linda Landini and Aurelio Leone
Affiliation:
Keywords: Epidemiological transition, hypertension, cardiovascular disorders, trial(s), cost-benefit ratio, smoking, lipoproteins, vulnerable plaque, thrombin, diabetes
Abstract: Epidemiological surveys demonstrate undoubtedly that cardiovascular disorders caused or associated with hypertension are at a high risk of non-fatal or fatal events and occurring with a great rate. Ischaemic heart disease with effort angina and myocardial infarction, often unrecognized myocardial infarction, stroke and transient ischaemic attack may be observed more frequently than other cardiovascular disorders in hypertensive patients.
Large-scale trials do not support the hypothesis that effective benefits are reached by current non-pharmacological or pharmacological prevention which need enormous costs to public health.
Lowering blood pressure is the main target to reach in an attempt to reduce cardiovascular complications in hypertensive patients. Therefore, the costs-benefit ratio, which estimates public health costs, needs yet marked improvement since the public health expenses are heaviest with results that do not support the economic effort.
Statistically, quantitative measures to modify the current regimen need to better evaluate both public health costs and reached benefits.
Export Options
About this article
Cite this article as:
Leone Aldo, Landini Linda and Leone Aurelio, Epidemiology and Costs of Hypertension-related Disorders, Current Pharmaceutical Design 2011; 17 (28) . https://dx.doi.org/10.2174/138161211798157739
DOI https://dx.doi.org/10.2174/138161211798157739 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological and Biological Activities of Benzazepines: An Overview
Current Bioactive Compounds Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Current Pharmaceutical Biotechnology Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
Cardiovascular & Hematological Disorders-Drug Targets Cyclodextrins as Food Additives and in Food Processing
Current Nutrition & Food Science Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research
Drug Metabolism Letters Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets The LDL-Receptor and its Molecular Properties: From Theory to Novel Biochemical and Pharmacological Approaches in Reducing LDL-cholesterol
Current Medicinal Chemistry Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine